Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.41 |
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.41 |
| ▸ | RXRA | P19793 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | F7 | P08709 | 3/20 | 0.35 |
| ▸ | F3 | P13726 | 3/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16881614 | 0.89 | NR1I2 (0.33) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL16881617 | 0.89 | NR1I2 (0.33) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL16881611 | 0.89 | NR1I2 (0.33) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL14899320 | 0.80 | LMNA (0.50) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL12044968 | 0.79 | ADORA3 (0.47) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL12116747 | 0.79 | ALDH1A1 (0.46) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL6897010 | 0.79 | ALDH1A1 (0.46) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL15113713 | 0.79 | ADORA3 (0.34) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL6896864 | 0.77 | ALDH1A1 (0.44) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL12116842 | 0.77 | ALDH1A1 (0.44) | ADORA3NR1I2PTGS2PGRPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170196848-A1 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives | ALKERMES PHARMA IRELAND LTD (IE) | 2017-07-13 | — | — | US | disclosed |
| US-9585965-B2 | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-03-07 | — | — | US | disclosed |
| US-20150320875-A1 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives | ALKERMES PHARMA IRELAND LTD (IE) | 2015-11-12 | — | — | US | disclosed |
| US-20150210712-A1 | Prodrugs of Secondary Amine Compounds | ALKERMES PHARMA IRELAND LTD (IE) | 2015-07-30 | — | — | US | disclosed |
| US-9072788-B2 | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-07-07 | — | — | US | disclosed |
| US-8969337-B2 | Prodrugs of secondary amine compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-03-03 | — | — | US | disclosed |
| US-20130184265-A1 | Prodrugs of Secondary Amine Compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2013-07-18 | — | — | US | disclosed |
| US-20110319422-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES | ALKERMES, INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210712-A1 | Prodrugs of Secondary Amine Compounds | HNMT, MAOB, UGT1A1 | ADORA3 315/4885NR1I2 782/4885PTGS2 1710/4885 |
| US-20150320875-A1 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives | PHPT1, SI, CA6 | ADORA3 1272/4885NR1I2 2623/4885PTGS2 1739/4885 |
| US-20170196848-A1 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives | PHPT1, SI, CA6 | ADORA3 1272/4885NR1I2 2623/4885PTGS2 1739/4885 |
| US-20130184265-A1 | Prodrugs of Secondary Amine Compounds | HNMT, MAOB, UGT1A1 | ADORA3 315/4885NR1I2 782/4885PTGS2 1710/4885 |
| US-20110319422-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES | PHPT1, SI, CA6 | ADORA3 1272/4885NR1I2 2623/4885PTGS2 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.